Page last updated: 2024-08-05 12:28:53
dimethoxyflavone
Any methoxyflavone with two methoxy substituents.
ChEBI ID: 23798
Members (19)
| Member | Definition | Role |
|---|---|---|
| 3,3'-di-o-methylquercetin | A dimethoxyflavone that is quercetin in which the hydroxy groups at position 3 and 3' have been replaced by methoxy groups. It has been isolated from several plant species and exhibits anti-bacterial and anti-cancer properties. | 3,3'-dimethylquercetin |
| 3,7-dimethoxy-5,3',4'-trihydroxyflavone | A dimethoxyflavone that the 3,7-di-O-methyl derivative of quercetin. | 3',4',5-trihydroxy-3,7-dimethoxyflavone |
| 4',6-dihydroxy-5,7-dimethoxyflavone | A dimethoxyflavone that is the 5,7-dimethyl ether derivative of scutellarein. | 4',6-dihydroxy-5,7-dimethoxyflavone |
| 5,4'-dihydroxy-7,3'-dimethoxyflavone | A dimethoxyflavone that is luteolin in which the hydroxy groups at positions 7 and 3' are replaced by methoxy groups. | velutin |
| 5,7-dihydroxy-4',6-dimethoxyflavone | A dimethoxyflavone that is the 6,4'-dimethyl ether derivative of scutellarein. | pectolinarigenin |
| 5,7-dimethoxyflavone | A dimethoxyflavone that is the 5,7-dimethyl ether derivative of chrysin. | chrysin 5,7-dimethyl ether |
| 5,7,3'-trihydroxy-3,4'-dimethoxyflavone | A dimethoxyflavone that is the 3,4'-dimethyl ether derivative of quercetin. Isolated from Combretum quadrangulare, it exhibits antineoplastic activity. | quercetin 3,4'-dimethyl ether |
| apigenin dimethylether | A dimethoxyflavone that is the 7,4'-dimethyl ether derivative of apigenin. | apigenin 7,4'-dimethyl ether |
| axillarin | A dimethoxyflavone that is the 3,6-dimethyl ether derivative of quercetagetin. | axillarin |
| cirsiliol | A dimethoxyflavone that is flavone substituted by methoxy groups at positions 6 and 7 and hydroxy groups at positions 5, 3' and 4' respectively. | cirsiliol |
| cirsimaritin | A dimethoxyflavone that is flavone substituted by methoxy groups at positions 6 and 7 and hydroxy groups at positions 5 and 4' respectively. | cirsimaritin |
| ermanin | A dimethoxyflavone that is kaempferol in which the hydroxy groups at position 3 and 4' have been replaced by methoxy groups. It is a component of bee glue and isolated from several plant species including Tanacetum microphyllum. | 3,4'-dimethylkaempferol |
| jaceosidin | A trihydroxyflavone that is flavone with hydroxy groups at positions 5, 7 and 4' and methoxy groups at positions 3' and 6. Isolated from Salvia tomentosa and Artemisia asiatica, it exhibits anti-allergic, anti-inflammatory and apoptosis inducing activties. | jaceosidin |
| ladanein | A dimethoxyflavone that is scutellarein in which the hydroxy groups at positions 4' and 7 are replaced by methoxy groups. It is an effective anti-HCV agent. | ladanein |
| ombuine | A dimethoxyflavone that is quercetin in which the hydroxy groups at positions 7 and 4' are replaced by methoxy groups. Isolated from Cyperus teneriffae, it exhibits anti-inflammatory activity. | ombuin |
| pectolinarin | A disaccharide derivative that consists of pectolinarigenin substituted by a 6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. | pectolinarin |
| rhamnazin | A dimethoxyflavone that is quercetin in which the hydroxy groups at the 3' and 7 positions have been replaced by methoxy groups. | rhamnacene |
| syringetin | A dimethoxyflavone that is myricetin in which the hydroxy groups at positions 3' and 5' have been replaced by methoxy groups. | syringetin |
| tricin | The 3',5'-di-O-methyl ether of tricetin. Known commonly as tricin, it is a constituent of rice bran and has been found to potently inhibit colon cancer cell growth. | 3',5'-di-O-methyltricetin |
Research
Studies (445)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 13 (2.92) | 18.7374 |
| 1990's | 27 (6.07) | 18.2507 |
| 2000's | 103 (23.15) | 29.6817 |
| 2010's | 223 (50.11) | 24.3611 |
| 2020's | 79 (17.75) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 15 (2.80%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 521 (97.20%) | 84.16% |